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Abstract
It is widely accepted that thyroid hormone replacement for patients with hypothyroidism can be fully
accomplished with levothyroxine monotherapy, as assessed by serum thyroid function tests.
However, approximately 10% of hypothyroid patients are dissatisfied with the outcome of
levothyroxine monotherapy, and physicians continue to report benefits from combined
levothyroxine-triidothyronine therapy for some hypothyroid patients. Recently, a large prospective
study reported that the benefit of the combined levothyroxine-triidothyronine therapy is associated
with the Thr92Ala polymorphism in the type 2 deiodinase gene, which is present in about 15% of the
general population. If confirmed, these findings indicate that personalized medicine is rapidly catching
up with modern thyroidology.
Introduction and context
Hypothyroidism is one of the most common endo-
crine disorders, affecting about 4% of the adult US
population [1], and is caused primarily by autoim-
mune thyroiditis. Even though it is recognized that
3,5,3
0-triiodothyronine (T3) is the biologically active
form of thyroid hormone, for decades replacement
therapy has been based on levothyroxine (L-T4)
monotherapy [2]. This rationale stems from the
existence of iodothyronine deiodinases, enzymes that
activate thyroxine (T4) to T3 outside of the thyroid
parenchyma and generate most of the circulating T3
[3]. However, large community-based studies have
reported that a subset (about 10%) of hypothyroid
patients on L-T4 monotherapy exhibit significant
impairment in psychological well-being, even when
serum thyroid function tests are within the normal
range [4,5]. This suggests that these important neuro-
cognitive parameters may not be completely restored
in these hypothyroid patients when kept on L-T4
monotherapy. These findings create the need for
alternative therapeutic approaches for hypothyroid
patients that do not do well on L-T4 monotherapy,
including the use of desiccated animal thyroid or
combined therapy with L-T4 and 3,5,3
0-L-triiodothyro-
nine (L-T3) (T4/T3). In the latter case, studies have
been hampered due to formulation issues, given that
T4 has a much longer half-life and the current lack of a
long acting preparation of L-T3.
T3 and T4 are found at a ratio of approximately 1:15 in
the human thyroglobulin molecule [6], and this is
unlikely to be markedly affected by the intrathyroidal
conversion of T4 to T3. Thus, one would think that in
order to mimic normal thyroidal secretion, thyroid
hormone replacement therapy should be based on the
combination of L-T4 and L-T3 at similar ratios as found
in human thyroglobulin. However, for decades it has
been known that T4 can be activated outside the thyroid
gland to T3 via iodothyronine deiodinases D1 and D2.
These are highly homeostatic enzymes that adjust their
catalytic activities according to the plasma levels of T4
and T3. In fact, this paradigm is supported by extensive
literature that has served as the basis for the guidelines
set forth by the American Thyroid Association recom-
mending L-T4 monotherapy as the primary choice
for thyroid hormone replacement in patients with
hypothyroidism [7].
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a total of 1216 patients indicated that T4/T3 combina-
tion therapy provided no advantage when compared
with standard L-T4 monotherapy in any of the following
parameters: bodily pain, depression, anxiety, fatigue,
quality of life, body weight, total serum cholesterol and
triglycerides, serum low-density lipoprotein, and high-
density lipoprotein, and demonstrated no difference in
adverse events [8]. A second meta-analysis including a
total of 1243 patients suggested that T4/T3 combination
therapy is beneficial for the psychological and physical
well-being of patients previously on L-T4 monotherapy,
but there was no statistically significant difference in the
other variables [9]. Only one trial found a significant
benefit of T4/T3 combination therapy compared with
L-T4 monotherapy [10], but it is not clear whether these
findings were related to the cause of hypothyroidism, as
was later suggested [11].
Recent advances
It is well accepted that, in humans, most circulating T3 is
derived from extrathyroidal deiodination of T4 via D2 [3];
thus, it makes sense to hypothesize that defects in D2
expression/activitycould interfere withthe efficacy ofL-T4
monotherapy. In recent years, several polymorphisms
have been reported for the gene encoding D2 (DIO2),
including some associated with insulin resistance, obesity
[12], and hypertension [13], to name but a few. However,
these findings have been restricted to specific populations
and a more universal corollary is still missing. Central to
this problem is whether any of the DIO2 polymorphisms
reportedtodateaffecttheactivityand/orkineticproperties
of D2. The single nucleotide polymorphism A/G in DIO2
predicts a threonine to alanine substitution at codon 92
(Thr92Ala)and,insubjectshomozygousforthe Alaallele,
D2 velocity was reported to be decreased in an early study
[14], but this may have been the result of an artifact [15].
With this in mind, Panicker et al. [16] asked whether
common variants in DIO2 could explain differences in
psychological morbidity and response to thyroid hor-
mone replacement therapy in 552 patients of the Weston
Area T4/T3 Study (WATTS) in the UK. Their results
indicated that the Thr92Ala polymorphism in DIO2 is
associated with both impaired baseline psychological
well-being in patients on L-T4 monotherapy and
enhanced response to combination T4/T3 therapy,
which could explain the biological mechanism of the
T3 requirement.
However, what could be the mechanistic basis for such
findings given that the DIO2 polymorphism did not
affect thyrotropin, T4, or T3 serum levels in the Panicker
et al. study? A rationale could be based on the fact that
D2 activity increases the intracellular T3 concentration
relatively independently of the serum concentration of
T3 [3]. Accordingly, DIO2 knockout mice have normal
serum T3 concentrations but only half as much T3 in
their brains as wild type [17]. Although not as severe as
in hypothyroid mice, the DIO2 knockout mice exhibited
clear defects in certain agility tasks when evaluated for
locomotion and agility, learning and memory, reflexes,
anxiety, and exploratory levels. Furthermore, these
animals are also known for exhibiting defects in adaptive
thermogenesis and thermal homeostasis because of the
role played by D2 in brown adipose tissue [18,19].
Whether these findings could serve as the basis for the
improved psychological well-being and quality of life
reportedinpatientsreceivingcombinationT4/T3therapy
remains to be determined.
Implications for clinical practice
The overwhelming evidence available in the literature
supports the notion that L-T4 monotherapy provides
adequate thyroid hormone replacement in patients with
hypothyroidism. A small subset of hypothyroid patients
does seem to have a better quality of life and perform
better on cognitive tests when placed on combination
T4/T3 therapy. According to one large study, this could
be explained by the Thr92Ala polymorphism in the
DIO2 gene, which is present in about 15% of the general
population. While a prospective trial studying the effect
of the Thr92Ala polymorphism on the neuropsychiatric
response to combined T3/T4 versus L-T4 monotherapy
has yet to be carried out, it is fascinating to contemplate
the notion that personalized medicine is rapidly catching
up with modern thyroidology.
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